Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $132
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Sumant Kulkarni maintains a 'Buy' rating on Neurocrine Biosciences (NASDAQ:NBIX) and raises the price target from $130 to $132.
August 04, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity maintains a 'Buy' rating on Neurocrine Biosciences and raises the price target to $132.
The news is directly about Neurocrine Biosciences. The 'Buy' rating maintained by Canaccord Genuity and the increase in price target from $130 to $132 indicates a positive outlook for the company. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100